The figure shows that <i>R</i>₀ decreases significantly under control strategies, particularly at temperatures near the peak transmission range, indicating the effective... by Lukas Degu Petros (22097332)

Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. by Chen Lu (135200)

Subjects:

Effect of BM-MSCs in improving DCS induced lung injury. by Chen Lu (135200)

Subjects:

The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Mice subjected to chronic stress and provided with HRW exhibited a significant reduction in oxidative stress levels. by Qi He (384033)

Mice subjected to chronic stress and provided with HRW exhibited a significant reduction in lipid peroxidation levels. by Qi He (384033)

Cases and deaths of LC from the Chinese Annual Cancer Registry, 2004–2018. by Ze-Xing Zhang (18074512)

Subjects: “…although epidemiological improvements…”

Proposed model of apoptotic-like programmed cell death (AL-PCD) in plants. by Bikram Poudel (15989201)

Subjects:

MAGMAS inhibition induces medulloblastoma cell death. by Zahra Motahari (6814013)

Subjects:

Forest plot of the improvement in primary endpoints. by Jin-Min Gu (17915039)

Subjects:

Forest plot of the second endpoint of the clinical symptom improvement. by Jin-Min Gu (17915039)

Subjects:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Overview of the WeARTolerance program. by Ana Beato (20489933)

Subjects:

Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

Changes in LC cases and deaths in male and female from 2004 to 2018, decomposed by three population-level determinants: population aging, population growth and epidemiological chan... by Ze-Xing Zhang (18074512)

Subjects: “…although epidemiological improvements…”

BT9 did not improve survival in the orthotopic xenograft model of D425 medulloblastoma. by Zahra Motahari (6814013)

Subjects:

Percentage distribution of maternal deaths by cause of death, PDHS 2007 and PMMS 2019. by Farid Midhet (17403945)

Subjects:

Frontier Analysis: Countries with high potential for improvement in the burden of injuries caused by fire, heat, and hot substances in 2021. by Shi Huang (125861)